Literature DB >> 15252292

Using daily interactive voice response technology to measure drinking and related behaviors in a pharmacotherapy study.

Henry R Kranzler1, Khamis Abu-Hasaballah, Howard Tennen, Richard Feinn, Kevin Young.   

Abstract

BACKGROUND: Interactive voice response technology (IVR) allows investigators to collect daily measures of drinking, medication adherence, mood, and other treatment-relevant variables that may change day to day during a clinical trial. Despite these advantages, no published studies have used IVR in alcohol pharmacotherapy trials.
METHODS: Subjects provided daily data via IVR during the 12-week treatment period. Seven subjects completed the trial.
RESULTS: We found a high level of participant adherence to the IVR protocol, higher levels of drinking reported by IVR than by a commonly used recall method, and distinct within-day associations between daily mood and alcohol consumption: these could not be obtained through traditional assessment methods.
CONCLUSIONS: IVR seems to be feasible for the collection of daily indicators of treatment outcomes and processes in pharmacotherapy studies among problem drinkers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15252292     DOI: 10.1097/01.alc.0000130806.12066.9c

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  35 in total

Review 1.  Interactive voice response technology to measure HIV-related behavior.

Authors:  Kerstin E E Schroder; Christopher J Johnson
Journal:  Curr HIV/AIDS Rep       Date:  2009-11       Impact factor: 5.071

2.  Post-treatment outcomes in a double-blind, randomized trial of sertraline for alcohol dependence.

Authors:  Henry R Kranzler; Stephen Armeli; Howard Tennen
Journal:  Alcohol Clin Exp Res       Date:  2011-10-07       Impact factor: 3.455

3.  Changes in substance use-related health risk behaviors on the timeline follow-back interview as a function of length of recall period.

Authors:  Anne Buu; Runze Li; Maureen A Walton; Hanyu Yang; Marc A Zimmerman; Rebecca M Cunningham
Journal:  Subst Use Misuse       Date:  2014-03-06       Impact factor: 2.164

4.  Data equivalency of an interactive voice response system for home assessment of back pain and function.

Authors:  William S Shaw; Santosh K Verma
Journal:  Pain Res Manag       Date:  2007       Impact factor: 3.037

5.  5-HTTLPR genotype and daily negative mood moderate the effects of sertraline on drinking intensity.

Authors:  Henry R Kranzler; Stephen Armeli; Howard Tennen; Jonathan Covault
Journal:  Addict Biol       Date:  2012-11-12       Impact factor: 4.280

Review 6.  Use of novel technology-based techniques to improve alcohol-related outcomes in clinical trials.

Authors:  Eugenia M Gurvich; George A Kenna; Lorenzo Leggio
Journal:  Alcohol Alcohol       Date:  2013-08-17       Impact factor: 2.826

7.  Self-efficacy mediates the effects of topiramate and GRIK1 genotype on drinking.

Authors:  Henry R Kranzler; Stephen Armeli; Reagan Wetherill; Richard Feinn; Howard Tennen; Joel Gelernter; Jonathan Covault; Timothy Pond
Journal:  Addict Biol       Date:  2014-12-15       Impact factor: 4.280

8.  Within-person associations between daily motivation and self-efficacy and drinking among problem drinkers in treatment.

Authors:  Jon Morgenstern; Alexis Kuerbis; Jessica Houser; Frederick J Muench; Sijing Shao; Hayley Treloar
Journal:  Psychol Addict Behav       Date:  2016-08-25

9.  The Recovery Line: A pilot trial of automated, telephone-based treatment for continued drug use in methadone maintenance.

Authors:  Brent A Moore; Tera Fazzino; Declan T Barry; David A Fiellin; Christopher J Cutter; Richard S Schottenfeld; Samuel A Ball
Journal:  J Subst Abuse Treat       Date:  2013-01-30

10.  Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment.

Authors:  Jennifer W Tidey; Peter M Monti; Damaris J Rohsenow; Chad J Gwaltney; Robert Miranda; John E McGeary; James MacKillop; Robert M Swift; David B Abrams; Saul Shiffman; Jean A Paty
Journal:  Alcohol Clin Exp Res       Date:  2007-11-20       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.